Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease

Molecular Immunology

Volumn 44, Issue 10, 2007, Pages 2497-2506

  O'Sullivan, Lynda A ^a   Liongue, Clifford ^a   Lewis, Rowena S ^a   Stephenson, Sarah E M ^a   Ward, Alister C ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Cytokine receptor; Inflammatory diseases; Jak Stat Socs

Indexed keywords

CYTOKINE RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN RECEPTOR; JANUS KINASE; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; VIRUS RECEPTOR;

ASTHMA; AUTOIMMUNE DISEASE; BLOOD DISEASE; CHRONIC NEUTROPHILIC LEUKEMIA; COMBINED IMMUNODEFICIENCY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFLAMMATORY DISEASE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UVEITIS;

ANIMALS; HEMATOLOGIC DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; JANUS KINASES; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 33846903838     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.11.025     Document Type: Review

References (105)

1. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
2. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 6934-6938
3. Blumberg H., Conklin D., Xu W., Grossmann A., Brender T., Carollo S., Eagan M., Foster D., Haldeman B.A., and Hammond A. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104 (2001) 9-19
4. Bole-Feysot C., Goffin V., Edery M., Binart N., and Kelly P.A. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 19 (1998) 225-268
5. Boulay J.L., O'Shea J.J., and Paul W.E. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 19 (2003) 159-163
6. Bousquet M., Quelen C., De Mas V., Duchayne E., Roquefeuil B., Delsol G., Laurent G., Dastugue N., and Brousset P. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24 (2005) 7248-7252
7. Bovolenta C., Camorali L., Lorini A.L., Ghezzi S., Vicenzi E., Lazzarin A., and Poli G. Constitutive activation of Stats upon in vivo human immunodeficiency virus infection. Blood 12 (1999) 4202-4209
8. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol. 22 (2004) 625-655
9. Calo V., Migliavacca M., Bazan V., Macaluso M., Buscemi M., Gebbia N., and Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. Cell. Physiol. 197 (2003) 157-168
10. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., and Jove R. Constitutive activation of Stat3 confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
11. Chen M., Cheng A., Chen Y.Q., Hymel A., Hanson E.P., Kimmel L., Minami Y., Taniguchi T., Changelian P.S., and O'Shea J.J. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 6910-6915
12. Chen C.Y., Tsay W., Tang J.L., Shen H.L., Lin S.W., Huang S.Y., Yao M., Chen Y.C., Shen M.C., Wang C.H., and Tien H.F. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 37 (2003) 300-305
13. Conti P., Kempuraj D., Frydas S., Kandere K., Boucher W., Letourneau R., Madhappan B., Sagimoto K., Christodoulou S., and Theoharides T.C. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol. Lett. 88 (2003) 171-174
14. de Groot R.P., Coffer P.J., and Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell. Signal. 10 (1998) 619-628
15. de la Chapelle A., Träskelin A.L., and Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 4495-4499
16. Devos R., Guisez Y., Van der Heyden J., White D.W., Kalai M., Fountoulakis M., and Plaetinck G. Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding. J. Biol. Chem. 272 (1997) 18304-18310
17. Di Stefano A., Caramori G., Capelli A., Gnemmi I., Ricciardolo F.L., Oates T., Donner C.F., Chung K.F., Barnes P.J., and Adcock I.M. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur. Respir. J. 24 (2004) 78-85
18. Dirksen U., Nishinakamura R., Groneck P., Hattenhorst U., Nogee L., Murray R., and Burdach S. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J. Clin. Invest. 100 (1997) 2211-2217
19. Dolled-Filhart M., Camp R.L., Kowalski D.P., Smith B.L., and Rimm D.L. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin. Cancer Res. 9 (2003) 594-600
20. Dong F., Brynes R.K., Tidow N., Welte K., Löwenberg B., and Touw I.P. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. New Engl. J. Med. 333 (1995) 487-493
21. Dupuis S., Dargemont C., Fieschi C., Thomassin N., Rosenzweig S., Harris J., Holland S.M., Schreiber R.D., and Casanova J.-L. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293 (2001) 300-303
22. Egan P.J., Lawlor K.E., Alexander W.S., and Wicks I.P. Suppressor of cytokine-1 regulates acute inflammatory arthritis and T cell activation. J. Clin. Res. 111 (2003) 915-924
23. Egwuagu C.E., Yu C., Li Z., and Nussenblatt R.B. SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy. J. Autoimmun. 24 (2005) 39-46
24. Elson G.C., Lelievre E., Guillet C., Chevalier S., Plun-Favreau H., Froger J., Suard I., de Coignac A.B., Delneste Y., Bonnefoy J.Y., Gauchat J.F., and Gascan H. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. 3 (2000) 867-872
25. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H., Miyazaki T., Leonor N., Taniguchi T., Fujita T., Kanakura Y., Komiya S., and Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387 (1997) 921-924
26. Ernst M., Inglese M., Waring P., Campbell I.K., Bao S., Clay F.J., Alexander W.S., Wicks I.P., Tarlinton D.M., Novak U., Heath J.K., and Dunn A.R. Defective gp130-mediated signal transducer and activator of transcription (STAT) results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J. Exp. Med. 194 (2001) 189-203
27. Fishley B., and Alexander W.S. Thrombopoietin signaling in physiology and disease. Growth Factors 22 (2004) 151-155
28. Frank S.J. Growth hormone signaling and its regulation: preventing too much of a good thing. Growth Horm. IGF Res. 11 (2001) 201-212
29. Fry T.J., and Mackall C.L. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J. Immunol. 174 (2005) 6571-6576
30. Fujimoto M., Tsutsui H., Xinshou O., Tokumoto M., Watanabe D., Shima Y., Yoshimoto T., Hirakata H., Kawase I., Nakanishi K., Kishimoto T., and Naka T. Inadequate induction of suppressor of cytokine-1 causes systemic autoimmune diseases. Int. Immunol. 16 (2004) 303-314
31. Gaffen S.L. Domains of the interleukin 2 receptor. Cytokine 14 (2001) 63-77
32. Gale R.E., Freeburn R.W., Khwaja A., Chopra R., and Linch D.C. A truncated isoform of the human beta chain common to the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 with increased mRNA expression in some patients with acute leukemia. Blood 91 (1998) 54-63
33. Gits J., van Leeuwen D., Carroll H.P., Touw I.P., and Ward A.C. Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors. Leukemia 20 (2007) 2111-2118
34. Hayakawa F., Towatari M., Iida H., Wakao H., Kiyoi H., Naoe T., and Saito H. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br. J. Haematol. 101 (1998) 521-528
35. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., and Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem. J. 334 (1998) 297-314
36. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell 80 (1995) 213-223
37. Hilton D.J., Richardson R.T., Alexander W.S., Viney E.M., Willson T.A., Sprigg N.S., Starr R., Nicholson S.E., Metcalf D., and Nicola N.A. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 114-119
38. Hiraoka O., Anaguchi H., and Ota Y. Evidence for the ligand-induced conversion from a dimer to a tetramer of the granulocyte colony-stimulating factor receptor. FEBS Lett. 356 (1994) 255-260
39. Huang L.J., Constantinescu S.N., and Lodish H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell 8 (2001) 1327-1338
40. Hwang S.Y., Hertzog P.J., Holland K.A., Sumarsono S.H., Tymms M.J., Hamilton J.A., Whitty G., Bertoncello I., and Kola I. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11284-11288
41. Ito H. IL-6 and Crohn's disease. Curr. Drug Targets Inflamm. Allergy 2 (2003) 125-130
42. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434 (2005) 1144-1148
43. Jeanmougin F., Thompson J.D., Gouy M., Higgins D.G., and Gibson T.J. Multiple sequence alignment with Clustal X. Trends Biochem. Sci. 23 (1998) 403-405
44. Joos S., Kupper M., Ohl S., von Bonin F., Mechtersheimer G., Bentz M., Marynen P., Moller P., Pfreundschuh M., Trumper L., and Lichter P. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 60 (2000) 452-549
45. Jouanguy E., Dupuis S., Pallier A., Doffinger R., Fondaneche M.C., Fieschi C., Lamhamedi-Cherradi S., Altare F., Emile J.F., Lutz P., Bordigoni P., Cokugras H., Akcakaya N., Landman-Parker J., Donnadieu J., Camcioglu Y., and Casanova J.L. In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J. Clin. Invest. 105 (2000) 1429-1436
46. Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.Q., Lal B.K., Lloyd A.R., Kelvin D.J., Staples J.E., Ortaldo J.R., et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6374-6378
47. Kishimoto T., Taga T., and Akira S. Cytokine signal transduction. Cell 76 (1994) 253-262
48. Kotenko S.V., and Langer J.A. Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol. 4 (2004) 593-608
49. Kotenko S.V., and Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19 (2000) 2557-2565
50. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., and Donnelly R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4 (2003) 69-77
51. Kovanen P.E., and Leonard W.J. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their pathways. Immunol. Rev. 202 (2004) 67-83
52. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New Engl. J. Med. 352 (2005) 1779-1790
53. Kuperman D.A., Huang X., Koth L.L., Chang G.H., Dolganov G.M., Zhu Z., Elias J.A., Sheppard D., and Erle D.J. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 8 (2002) 885-889
54. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffe M., Berthou C., Lessard M., Berger R., Ghysdael J., and Bernard O.A. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278 (1997) 1309-1312
55. Lee J.W., Kim Y.G., Soung Y.H., Han K.J., Kim S.Y., Rhim H.S., Min W.S., Nam S.W., Park W.S., Lee J.Y., Yoo N.J., and Lee S.H. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25 (2006) 1434-1436
56. Leonard W.J., and Lin J.X. Cytokine receptor pathways. J. Allergy Clin. Immunol. 105 (2000) 877-888
57. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., and Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
58. Lieschke G.J., Grail D., Hodgson G., Metcalf D., Stanley E., Cheers C., Fowler K.J., Basu S., Zhan Y.F., and Dunn A.R. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor deficiency, and impaired neutrophil mobilization. Blood 84 (1994) 1737-1746
59. Lin T.S., Mahajan S., and Frank D.A. STAT in the pathogenesis and treatment of leukemias. Oncogene 19 (2000) 2496-2504
60. Liu T.C., Lin S.F., Chang J.G., Yang M.Y., Hung S.Y., and Chang C.S. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br. J. Haematol. 123 (2003) 654-661
61. Lovato P., Brender C., Agnholt J., Kelsen J., Kaltoft K., Svejgaard A., Eriksen K.W., Woetmann A., and Odum N. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J. Biol. Chem. 278 (2003) 16777-16781
62. Mangi M.H., and Newland A.C. Interleukin-3 in hematology and oncology: current state of knowledge and future directions. Cytokines Cell. Mol. Ther. 5 (1999) 87-95
63. Matsumoto A., Masuhara M., Mitsui K., Yokouchi M., Ohtsubo M., Misawa H., Miyajima A., and Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89 (1997) 3148-3154
64. Neculai D., Neculai A.M., Verrier S., Straub K., Klumpp K., Pfitzner E., and Becker S. Structure of the unphosphorylated Stat5a dimer. J. Biol. Chem. 280 (2005) 40782-40787
65. Ozaki K., and Leonard W.J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277 (2002) 29355-29358
66. Ozaki A., Seki Y., Fukushima A., and Kubo M. The control of allergic conjunctivitis by suppressor of cytokine (SOCS)3 and SOCS5 in a murine model. J. Immunol. 175 (2005) 5489-5497
67. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper J.L., Kramer J., Conklin D., Presnell S.R., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant F.J., Lofton-Day C., Gilbert T., Raymond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly R.D., and Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
68. Paul W.E. Interleukin-4: signaling mechanisms and control of T cell differentiation. Ciba Found. Symp. 204 (1997) 208-216
69. Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J., Philip P., Monpoux F., Van Rompaey L., Baens M., Van den Berghe H., and Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90 (1997) 2535-2540
70. Pericle F., Pinto L.A., Hicks S., Kirken R.A., Sconocchia G., Rusnak J., Dolan M.J., Shearer G.M., and Segal D.M. HIV-1 infection induces a selective reduction in Stat5 protein expression. J. Immunol. 160 (1998) 28-31
71. Pesu M., Candotti F., Husa M., Hofmann S.R., Notarangelo L.D., and O'Shea J.J. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol. Rev. 203 (2005) 127-142
72. Puel A., Ziegler S.F., Buckley R.H., and Leonard W.J. Defective IL7R expression in T-B + NK + severe combined immunodeficiency. Nat. Genet. 20 (1998) 394-397
73. Remy I., Wilson I.A., and Michnick S.W. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283 (1999) 990-993
74. Renauld J.C. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat. Rev. Immunol. 3 (2003) 667-676
75. Richmond T.D., Chohan M., and Barber D.L. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 15 (2005) 146-155
76. Roboz G.J., and Rafii S. Interleukin-5 and the regulation of eosinophil production. Curr. Opin. Hematol. 6 (1999) 164-168
77. Roy B., Bhattacharjee A., Xu B., Ford D., Maizel A.L., and Cathcart M.K. IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J. Leukoc. Biol. 72 (2002) 580-589
78. Saharinen P., Takaluoma K., and Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20 (2000) 3387-3395
79. Sampath D., Castro M., Look D.C., and Holtzman M.J. Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. J. Clin. Invest. 103 (1999) 1353-1361
80. Santiago-Raber M.-L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., and Theofilopoulos A.N. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197 (2003) 777-788
81. Sarcar B., Ghosh A.K., Steele R., Ray R., and Ray R.B. Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase. Virology 322 (2004) 51-60
82. Sato N., and Miyajima A. Multimeric cytokine receptors: common versus specific functions. Curr. Opin. Cell Biol. 6 (1994) 174-179
83. Seki Y., Inoue H., Nagata N., Hayashi K., Fukuyama S., Matsumoto K., Komine O., Hamano S., Himeno K., Inagaki-Ohara K., Cacalano N., O'Garra A., Oshida T., Saito H., Johnston J.A., Yoshimura A., and Kubo M. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat. Med. 9 (2003) 1047-1054
84. Shaw M.H., Boyartchuk V., Wong S., Karaghiosoff M., Ragimbeau J., Pellegrini S., Muller M., Dietrich W.F., and Yap G.S. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 11594-11599
85. Shuai K., Halpern J., ten Hoeve J., Rao X., and Sawyers C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13 (1996) 247-254
86. Sigurdsson S., Nordmark G., Goring H.H., Lindroos K., Wiman A.C., Sturfelt G., Jonsen A., Rantapaa-Dahlqvist S., Moller B., Kere J.K.S., Widen E., Eloranta M.L., Julkunen H., Kristjansdottir H., Steinsson K., Alm G., Ronnblom L., and Syvanen A.C. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76 (2005) 528-537
87. Skinnider B.F., Elia A.J., Gascoyne R.D., Patterson B., Trumper L., Kapp U., and Mak T.W. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99 (2002) 618-626
88. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., Gilliland D.G., and Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
89. Takase H., Yu C.R., Liu X., Fujimoto C., Gery I., and Egwuagu C.E. Induction of suppressors of cytokine (SOCS) in the retina during experimental autoimmune uveitis (EAU): potential neuroprotective role of SOCS proteins. J. Neuroimmunol. 168 (2005) 118-127
90. Tamura K., Suzuki M., Arakawa H., Tokuyama K., and Morikawa A. Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int. Arch. Allergy Immunol. 131 (2003) 33-38
91. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G.J., Campfield L.A., Clark F.T., Deeds J., Muir C., Sanker S., Moriarty A., Moore K.J., Smutko J.S., Mays G.G., Wool E.A., Monroe C.A., and Tepper R.I. Identification and expression cloning of a leptin receptor, OB-R. Cell 83 (1995) 1263-1271
92. Testa U., Riccioni R., Diverio D., Rossini A., Lo Coco F., and Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia 18 (2004) 219-226
93. Touw I.P., and Dong F. Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene. Leuk. Res. 20 (1996) 629-631
94. Uze G., Lutfalla G., and Mogensen K.E. Alpha and beta interferons and their receptor and their friends and relations. J. Interferon Cytokine Res. 15 (1995) 3-26
95. Ward A.C. The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front. Biosci. 12 (2007) 608-618
96. Ward A.C., van Aesch Y.M., Gits J., Schelen A.M., de Koning J.P., van Leeuwen D., Freedman M.H., and Touw I.P. Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. J. Exp. Med. 190 (1999) 497-507
97. Ward A.C., Touw I., and Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95 (2000) 19-29
98. Ware C.B., Horowitz M.C., Renshaw B.R., Hunt J.S., Liggitt D., Koblar S.A., Gliniak B.C., McKenna H.J., Papayannopoulou T., Thoma B., Cheng L., Donovan P.J., Peschon J.J., Bartlett P.F., Willis C.R., Wright B.D., Carpenter M.K., Davison B.L., and Gearing D.P. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121 (1995) 1283-1299
99. Watford W.T., Hissong B.D., Bream J.H., Kanno Y., Muul L., and O'Shea J.J. By IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202 (2004) 139-156
100. Weber-Nordt R.M., Egen C., Wehinger J., Ludwig W., Gouilleux-Gruart V., Mertelsmann R., and Finke J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88 (1996) 809-816
101. Wolfler A., Erkeland S.J., Bodner C., Valkhof M., Renner W., Leitner C., Olipitz W., Pfeilstocker M., Tinchon C., Emberger W., Linkesch W., Touw I.P., and Sill H. A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood 105 (2005) 3731-3736
102. Yokota S., Saito H., Kubota T., Yokosawa N., Amano K., and Fujii N. Measles virus suppresses interferon-alpha pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex. Virology 306 (2003) 135-146
103. Yoshida K., Taga T., Saito M., Suematsu S., Kumanogoh A., Tanaka T., Fujiwara H., Hirata M., Yamagami T., Nakahata T., Hirabayashi T., Yoneda Y., Tanaka K., Wang W.Z., Mori C., Shiota K., Yoshida N., and Kishimoto T. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 407-411
104. Zhang J.G., Farley A., Nicholson S.E., Willson T.A., Zugaro L.M., Simpson R.J., Moritz R.L., Cary D., Richardson R., Hausman G., Kile B.J., Kent S.B.H., Alexander W.S., Metcalf D., Hilton D.J., Nicola N.A., and Baca M. The conserved SOCS box motif in suppressors of cytokine binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 2071-2076
105. Zhao Y., Wagner F., Frank S.J., and Kraft A.S. The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain. J. Biol. Chem. 270 (1995) 13814-13818